Race against time: can shorter Pre-Surgery treatment match longer course for aggressive prostate cancer?
NCT ID NCT07450599
Summary
This study aims to find the best treatment length before surgery for men with high-risk prostate cancer that hasn't spread. Researchers will compare giving two drugs (darolutamide plus hormone therapy) for either 12 weeks or 24 weeks before prostate removal surgery. The main goal is to see which duration better shrinks or eliminates cancer in the prostate before it's surgically removed.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH-RISK LOCALIZED PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
2nd affiliated Hos. Harbin Medical University
Harbin, Heilongjiang, 150086, China
-
Cancer Hospital, Chinese Academy of Medical Sciences
Beijing, 100000, China
-
China Medical University (CMU) - First Affiliated Hospital
Shenyang, 110001, China
-
Dongyang People's Hospital
Jinhua, Zhejiang, 322199, China
-
Fujian Medical University - The First Affiliated Hospital
Fuzhou, 350005, China
-
Huazhong University of Science and Technology - Tongji Medical College - Wuhan Union Hospital
Wuhan, 430022, China
-
Jinhua Municipal Central Hospital-Oncology Department
Jinhua, Zhejiang, 321000, China
-
Kunming Medical University (KMU) - Second Affiliated Hospital
Kunming, Yunnan, 650101, China
-
Lanzhou University - The Second Hospital (The Second Clinical Medical College of Lanzhou University)
Lanzhou, 730030, China
-
NJ Drum Tower Hospital, the Affil Hos of NJ Univ Med School
Nanjing, Jiangsu, 210008, China
-
Nanchang University - The First Affiliated Hospital
Nanchang, 330006, China
-
Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, 510515, China
-
Peking University First Hospital - Oncology Department
Beijing, 100034, China
-
Qilu Hosp., Shandong Univ.
Jinan, Shandong, China
-
Shanghai General Hospital
Shanghai, 200080, China
-
Shanghai Jiao Tong University School of Medicine (SJTUSM) - XinHua Hospital
Shanghai, 200092, China
-
Sichuan Cancer Hospital-Urology Department
Chengdu, 610041, China
-
The 2nd Hospital of Hebei Medical University
Shijiazhuang, Hebei, 050000, China
-
The Second Hospital of Anhui medical university
Hefei, Anhui, 230601, China
-
The Second Hospital of Tianjin Medical University
Tianjin, 300211, China
-
The first Affiliated Hospital of Guangzhou Medical University
Guangzhou, 510230, China
-
Wuhan University - Renmin Hospital (Wuhan University People's Hospital/Hubei Provincial People's Hospital)
Wuhan, 430060, China
-
Zhengzhou University - First Affiliated Hospital (Henan Medical University - First Affiliated Hospital)
Zhengzhou, 450052, China
Conditions
Explore the condition pages connected to this study.